IngredientsScientific name: Platycodon grandiflorum (Jacq.) A. DC. Researchers have identified 219 chemical constituents in Platycodon grandiflorum (Jacq.) A. DC, making it one of the more thoroughly characterized medicinal roots in East Asian herbal pharmacopoeia. It is the sole species of the genus Platycodon (family Campanulaceae), widely grown in Northeast Asia.
Common names: Platycodon root is commonly known in English as balloon flower root, a reference to the plant's distinctive balloon-shaped buds before flowering. Derived from Platycodon grandiflorus, it is commonly known as balloon flower root and is native to East Asia—including China, Korea, and Japan—where it has been used for centuries in traditional medicine, particularly in Traditional Chinese Medicine (TCM), where it is called Jie Geng (桔梗). In Korean it is known as doraji, and in Japanese traditional medicine it is called kikyo. Known as Platycodonis Radix or Jiegeng in Chinese, it is a well-known traditional Chinese medicine used for both medicinal and culinary purposes.
Botanical description and distribution: P. grandiflorum is a perennial herbaceous plant. It has been used for hundreds of years as a traditional prescription to relieve cough and eliminate phlegm, among other ailments. The root itself is the primary medicinal part, harvested after 2–3 years of growth for optimal saponin content. China has high levels of PG resources, most of which are exported to Korea, Japan, and Southeast Asia.
Common preparations and dosage forms: The plant has a long history of use as a traditional herbal medicine and, as a legal medicine and dietary supplement, is also frequently used as an ingredient in health foods and vegetable dishes. Commercially, it is cultivated widely and available as dried roots, extracts, teas, or supplements. In Korean cuisine, known as doraji, the root is prepared as a vegetable in dishes like bibimbap or namul (seasoned greens), often soaked to remove bitterness, and processed into syrups, liquors, or preserved fruits. In medicinal settings, it is most commonly administered as a water decoction, ethanol extract, powder, or standardized capsule. PG and its compound prescriptions are often used in dosage forms of decoction and leaching solution.
Platycodon root has been used for over 2,000 years in Traditional Chinese Medicine, with its first mention in classic medical texts like the Shennong Ben Cao Jing (Divine Farmer's Materia Medica). In TCM, it is classified as an herb that ventilates the lungs, dispels phlegm, and benefits the throat, with traditional use for respiratory disorders, pulmonary abscesses, and chest distress.
In terms of Chinese medical theories, TCM believes that the root of P. grandiflorum has the functions of relieving sore throat, eliminating phlegm, and draining pus, and is widely used in lung diseases and respiratory system disorders. It is categorized in TCM as an "ascending herb," meaning it helps direct the effects of a formula upward, often used to guide other herbs to the upper body or to the lungs.
Chinese doctors widely prescribed Platycodon grandiflorus A. DC. to treat lung carbuncles in ancient China. It was commonly prescribed for productive coughs, chest congestion, and tonsillitis, often paired with licorice root (Gan Cao) or other harmonizing herbs to enhance its soothing and clearing effects. Beyond its use as a single herb, platycodon has played a vital role in various traditional herbal combinations, being a key component of classic formulas like Bai He Gu Jin Tang and Qian Jin Zhi Chuan Tang, where it is combined with herbs such as licorice root, peony, and fritillaria.
The Ming Yi Bie Lu (《名医别录》) classified Jie Geng as having "slight toxicity" (有小毒), while other classical sources such as the Yao Xing Lun described it as non-toxic. The Chinese Pharmacopoeia does not list Jie Geng among its formally classified toxic herbs, but classical sources warrant caution.
In Korean traditional medicine, platycodon root has been widely used since ancient times as a traditional drug to treat cold, cough, and asthma. In Korean traditional medicine, platycodon root (called doraji) is similarly revered and is still widely used in teas, syrups, and soups to maintain lung and throat health.
In Korea, PG roots that have been cultivated for 4 years are used to treat bronchitis, asthma, pulmonary tuberculosis, diabetes, and inflammatory diseases. In Korea, the roots are added to salads, cold soup, vegetables, or just pan-fried and served on their own.
Japanese traditional (Kampo) medicine has been used to treat infectious diseases for a long time. The classic text Shokanron (Shanghanlun in Chinese) is one of the most important textbooks for infectious diseases in traditional Chinese and Kampo medicine, containing many formulas for infectious diseases used for the past 1,800 years and even in recent times. In particular, a combination drug of kakkonto, shosaikoto, Platycodon grandiflorum root, and gypsum (known as saikatsugekito) has been reported to be useful during past influenza pandemics.
Researchers have identified 219 chemical constituents in Platycodon grandiflorum (Jacq.) A. DC, encompassing 89 saponins, 11 flavonoids, 21 polysaccharides, 14 phenolic acids, six polyacetylenes, five sterols, 34 fatty acids, 17 amino acids, and 22 trace elements.
In the past few decades, P. grandiflorum has been reported to contain various chemical constituents such as triterpenoid saponins, flavonoids, phenolic acids, polyacetylenes, phytosterols, and polysaccharides. Platycodins, an oleanane-type pentacyclic triterpenoid saponin, are abundant in the roots of P. grandiflorum and are the major bioactive constituents of this plant.
Platycosides (saponins) from the roots of PG are characterized by a structure containing a triterpenoid aglycone and two sugar chains. The most pharmacologically studied individual saponin is Platycodin D (PLD). Platycodin D (PLD), an oleanane-type triterpenoid saponin, is one of the active substances in PG and has been revealed to have anti-inflammatory, anti-viral, anti-oxidation, anti-obesity, anticoagulant, spermicidal, and anti-tumor activities.
Platycodin D (PD) is one of the main saponins extracted from the root of Platycodon grandiflorum (Jacq.) A. DC., which has been used for decades as a traditional prescription to eliminate phlegm, relieve cough, reduce inflammation, lower blood pressure and blood sugar levels, and for weight loss.
Saponins, flavonoids, polysaccharides, and phenolic acids are the main active components of P. grandiflorum, which have significant antitussive, expectorant, anti-tumor, anti-oxidation, and hypoglycemic effects. Eleven distinct flavonoids have been identified from the root. These contribute to the plant's antioxidant activity.
Polysaccharides are the main components responsible for biological functions. Polysaccharides of Platycodon grandiflorum have anti-oxidative stress and immunomodulatory activities. Polysaccharides from P. grandiflorum specifically activate B cells and macrophages, but not T cells. Twenty-one distinct polysaccharides have been identified, including inulin-type fructans.
Multiple classes of phenolics have been isolated from P. grandiflorum root, including lignols, phenolics, neolignans, alkyl aryl ether-type lignans, furofuran-type lignans, benzofuran-type lignans, and dibenzylbutane-type lignans. Fourteen phenolic acids have been catalogued in the root. These compounds contribute independently to the plant's anti-inflammatory profile.
Six polyacetylenes and five sterols (including alpha-spinasterol and stigmast-7-enol) have been identified in the root, though these classes have received considerably less mechanistic study than the saponin fraction.
Studies have demonstrated that the relaxation of platycodin D (PD) in bronchial smooth muscle and its modulatory effects on the immune status of the respiratory tract mucosa are credited with the therapeutic effects of PG. The main effects of P. grandiflorum are cough relieving and expectorant. Multiple active ingredients identified in the available literature contribute to its antitussive and phlegm-removal actions.
The expectorant action of platycodin saponins has been attributed to local irritation of the gastric mucosa, which reflexively stimulates bronchial secretion and ciliary activity, loosening mucus and facilitating expectoration. Triterpenoid saponins are often considered expectorants; platycodins from Platycodon grandiflorus are cited in this context in the pharmacological literature.
Platycodin D (PLD), an effective triterpenoid saponin isolated from the root of Platycodon grandiflorum, has been reported to have anti-inflammatory, antitumor, and antioxidative effects. PLD inhibited LPS-induced NO and TNF-α production in RAW264.7 cells.
The suppression of NF-κB and activation of LXRα allowed PLD to repress mastitis as well. Fu et al. demonstrated that PLD could silence inflammation in rat microglia by activating the LXRα-ABCA1 signaling pathway to induce cholesterol flow. PLD decreased the production of TNF-α, IL-1β, and IL-6 in BV-2 cells.
The PI3K/mTOR signaling pathway was found to be inactivated, thereby restraining the activation of the full immune cell by inhibition of pro-inflammatory cytokines, as revealed by results indicating the prevention of high-glucose-induced inflammation response by PD.
Platycodin D is a triterpenoid saponin from Platycodon grandiflorus that has emerged as a promising natural anticancer lead. It suppresses tumor growth by engaging multiple cancer hallmarks, including induction of apoptosis and other programmed cell-death programs, inhibition of proliferation, and attenuation of invasion and metastasis.
PD-induced cancer cell death was associated with cytoplasmic pinocytic and autophagic vacuolation. Cellular energy levels were decreased by this compound, leading to the activation of AMP-activated protein kinase (AMPK). Additionally, compound C, an inhibitor of AMPK, completely prevented PD-induced vacuolation. These results suggest that PD induces cancer cell death associated with excessive vacuolation through AMPK activation when cellular energy levels are low.
Treatment with PD led to significant cell cycle arrest, thereby causing subsequent apoptosis. Regarding the cell growth inhibition mechanism, PD can downregulate the protein level of c-Myc rather than its mRNA level in a dose-dependent manner.
Research has also discovered that Platycodon grandiflorum (PG) reduced the expression of PD-1 on the surface of CD8+ T cells to exert antitumor effects in non-small cell lung cancer (NSCLC).
Platycodi radix activated AMPK/ACC phosphorylation in C2C12 myotubes and also suppressed adipocyte differentiation in 3T3-L1 cells. In experimental animals, it suppressed the weight gain of obese mice and ameliorated obesity-induced insulin resistance. It also reduced elevated circulating mediators, including triglyceride (TG), total cholesterol, leptin, resistin, and monocyte chemotactic protein (MCP)-1 in obesity.
Platycodon grandiflorum polysaccharide effectively alleviated the signs of metabolic syndrome, as demonstrated by reductions in body weight, hepatic steatosis, lipid profile, inflammatory response, and insulin resistance in obese mice.
Red Platycodon grandiflorus root extract (RPGE), which is made by steaming and drying Platycodon grandiflorus root several times, contains elevated levels of components such as saponins, including platycoside E and platycodin D. RPGE has been reported to have potent immune-enhancing effects by modulating the nuclear factor kappa B (NF-κB) signaling pathway in murine macrophage RAW 264.7 cells.
The pharmacokinetic profile of platycodin D is suboptimal, with studies showing extremely poor oral bioavailability and long absorption times, largely due to low intestinal permeability, first-pass metabolism, and active efflux mechanisms. The bioavailability of PLD could be improved by being prescribed with Glycyrrhiza uralensis Fisch. (licorice root). Literature indicates that platycodon root is poorly absorbed in the gastrointestinal tract, and oral administration effectively suppresses its hemolytic activity.
Traditional claim: The primary historical indication of platycodon root across all East Asian traditions is as an antitussive (cough suppressant) and expectorant for cough, phlegm production, sore throat, chest congestion, and bronchitis.
Preclinical evidence: In a chronic bronchitis model induced in rats by inhaling 2% sulfur dioxide (SO₂) for 30 minutes daily for 15 consecutive days, PD (2 mg/kg) and PD combined with Jiegeng polysaccharide (JGP) were administered orally. Both the PD group and PD + JGP groups exhibited significant reductions in lung tissue acid mucin secretion, mucin 2 expression, and TNF-α expression compared to the model group, suggesting that PD has a therapeutic effect on chronic bronchial inflammation and that the combined effect with JGP is enhanced.
Platycodon grandiflorum (PG) has been widely used for treating chronic bronchitis (CB). PLD inhibited LPS-induced acute lung injury in mice. PLD also had protective effects against OVA-induced allergic asthma in mice.
Allergic/immune respiratory evidence: In a study evaluating the biological effect of Platycodon root ethanol extract (PE) on bone marrow-derived mast cells (BMMC) after induction of allergic mediators by PMA plus calcium ionophore stimulation, the effect on production of several allergic mediators, including interleukin-6 (IL-6), prostaglandin D₂ (PGD₂), leukotriene C₄ (LTC₄), β-Hexosaminidase (β-Hex), and cyclooxygenase-2 (COX-2) protein, was investigated.
Evidence strength: Evidence for antitussive and expectorant effects is primarily preclinical (animal and in vitro models). Platycodonis Radix is a well-known traditional Chinese medicine used for both medicinal and culinary purposes, and its historical use as an antitussive and expectorant has been extensively documented. However, rigorous double-blind randomized controlled trials (RCTs) in humans for these specific indications are lacking. The preclinical evidence is mechanistically coherent with traditional claims, and the long historical record of use provides ethnopharmacological support, but robust clinical evidence remains limited.
Preclinical evidence: Multiple animal studies have investigated PG root's anti-obesity effects. The root of Platycodon grandiflorus, abundant in soluble polysaccharides, has a long history in traditional Asian diets and herbal medicine due to its anti-inflammatory activity and anti-obesity effects. In the past decade, researchers have discovered the new pharmacological potential of platycodin in the treatment of chronic conditions, including hyperlipidemia, hypertension, diabetes, and obesity.
Human clinical trial: Platycodon grandiflorus root extract (PGE) has shown various properties such as anti-hyperlipidemia, anti-diabetic, and anti-obesity, but mostly in animal studies. A preliminary study on the anti-obesity effect of PGE was conducted in 108 Korean adults (aged 20–60 years, BMI 23–30 kg/m²). Participants were randomly assigned to four groups and administered the placebo, PGE 571 mg, PGE 1142 mg, and PGE 2855 mg, independently, for 12 weeks. Body composition, nutrient intake, computed tomography scan, plasma adipokines, and hepatic/renal function markers were assessed. The PGE 571 mg group revealed a significant decrease in body fat mass and body fat percentage when compared with the placebo group. Moreover, the total abdominal and subcutaneous fat areas were significantly decreased following PGE 2855 mg supplementation.
Evidence strength: This was described as the first study to investigate the body fat loss effects of PGE in humans. The authors noted it was a preliminary study, intended to provide information on the approximate daily dosage of PGE for an upcoming main study. As a single, small, preliminary RCT with a primarily Korean adult population, these findings require replication before conclusions can be drawn. The preponderance of evidence remains animal-based.
Preclinical evidence: Accumulating evidence suggests the potential role of Platycodon grandiflorus root in immunomodulation in vitro and in vivo. Polysaccharides of Platycodon grandiflorum have anti-oxidative stress and immunomodulatory activities. A recent study also revealed that Platycodon grandiflorum polysaccharides have a certain balancing effect on the intestinal flora after exposure to PM2.5.
Human clinical trial: The immune-enhancing effects of red Platycodon grandiflorus root extract (RPGE) had been reported in vitro and in vivo, but there are few studies on humans. An 8-week randomized, double-blind, parallel, placebo-controlled clinical trial was conducted at the Gachon University Gil Medical Center, Incheon, South Korea. A total of 100 adults aged 20–75 years with white blood cell counts of 3,000–10,000 cell/µL were randomly divided into two groups (RPGE group, n=50; placebo group, n=50) using a computer-generated random list with a 1:1 allocation ratio. The subjects consumed RPGE (2 times/day, 2 tablets/time, 375 mg RPGE powder/tablet) or placebo for 8 weeks.
Evidence strength: This was a well-designed RCT in healthy adults with a clearly defined dose. However, it is a single study, used a specific preparation (red/steamed platycodon root extract, which differs from standard extracts), and focused on healthy subjects rather than those with compromised immunity. Findings are promising but preliminary. There are very few studies on immune-enhancing effects in humans, and broader replication is needed.
In vitro and animal evidence: Studies found that cells treated with platycodin D induce apoptosis on various types of cells, including breast cancer cells, gastric cancer cells, prostate cancer cells, bladder cancer cells, and hepatic stellate cells. Research discovered that Platycodon grandiflorum (PG) reduced the expression of PD-1 on the surface of CD8+ T cells to exert antitumor effects in non-small cell lung cancer (NSCLC). By combining systems pharmacology strategies and clinical data analysis, it was found that PG has the potential to immunomodulate T cells and suppress tumors. In vivo and in vitro experiments confirmed the antitumor effect of the combination of Platycodin D and Platycodin D3.
The biological effects of saponins include cytotoxic effects against cancer cells, neuroprotective activity, antiviral activity, and cholesterol-lowering effects.
Evidence strength — human: To date, no human clinical trials have evaluated PD's efficacy or safety in cancer patients. The data support platycodin D as a multi-target anticancer scaffold while underscoring the need for rigorous in vivo validation, standardized pharmacokinetic characterization, safety evaluation, and well-designed clinical studies to define its therapeutic potential. The anti-cancer evidence for platycodon root currently resides entirely in the preclinical domain, and no clinical conclusions can be drawn.
P. grandiflorum has been used in traditional oriental medicine for treating lung and respiratory diseases such as cough, cold, bronchitis, asthma, and sore throat. Results from previously published studies indicate that P. grandiflorum can have a relieving effect on cough and asthma; it has also been shown to exhibit extensive pharmacological effects, including anti-tumor, antioxidation, anti-inflammatory, and antibacterial activities.
Kim et al. discovered that platycodin could heal muscle injury by lowering the levels of serum lactate dehydrogenase (LDH), creatinine kinase (CK), and C-reactive protein, and suppressing matrix metalloproteinase (MMP).
Evidence strength: Anti-inflammatory activity is well-supported in preclinical (cell culture and animal) models across multiple inflammatory mediators and pathways (NF-κB, PI3K/mTOR, LXRα). Human clinical data directly evaluating anti-inflammatory endpoints is not currently available from the published literature.
PLD protected against alcohol-induced liver injury in mice. Additionally, Jiegeng shows potential in protecting the heart and liver. Jiegeng exhibits diverse pharmacological effects, including antitussive and anti-phlegm properties, anti-cancer activity, anti-inflammatory effects, immune regulation, antioxidant properties, anti-obesity, and antidiabetic effects. Additionally, Jiegeng shows potential in protecting the heart and liver. These findings are preclinical; no human hepatoprotective trials have been identified.
PLD was found to protect alloxan-induced diabetic mice via regulation of Treg/Th17 balance. In experimental animals, Platycodi radix suppressed the weight gain of obese mice and ameliorated obesity-induced insulin resistance. It also reduced elevated circulating mediators, including triglyceride (TG) and total cholesterol. The administration of Platycodi radix extracts also recovered the AMPK/ACC phosphorylation in the muscle of obese mice.
Evidence strength: All antidiabetic evidence is currently from animal models and in vitro systems. No human clinical trials specifically targeting glycemic outcomes with PG root as the primary intervention have been identified.
The following dosages are reported from specific sources and should not be construed as clinical recommendations.
No platycodin D treatment-related mortalities, clinical signs, or changes in body and organ weights, gross and histopathological observations against 14 principal organs were detected up to 2000 mg/kg in both female and male mice. Therefore, the LD50 and approximate LD of platycodin D after single oral treatment in both sexes were considered over 2000 mg/kg.
Results of genotoxic assays indicated that fermented PG extract induced neither mutagenicity nor clastogenicity. The acute toxicity test showed that FPGE did not affect animal mortality, clinical signs, body weight changes, or microscopic findings at ≤3000 mg/kg. The approximate lethal dose (ALD) of FPGE in SD rats was >3000 mg/kg.
In a 13-week subchronic toxicity assay, no dose of FPGE induced any significant change in mortality, clinical signs, body or organ weight, food consumption, ophthalmology, urinalysis, hematology, serum chemistry, gross findings, or histopathological examination in either sex of SD rat. The NOAEL for FPGE was set at 3000 mg/kg.
Intravenous administration of saponins may cause hemolysis, which is a safety concern restricting clinical application and product development. Nineteen saponins studied revealed hemolytic activity in human erythrocytes. Intravenous administration of saponins may cause hemolysis—a safety concern for clinical application. Hemolytic activity is correlated with the molecular structure of saponins. Compared to ursane or dammarane types, oleanane-type saponins have stronger hemolytic activity. The hemolytic activity of PLD, an oleanane-type saponin, has been demonstrated in laboratory settings.
However, when taken orally, these saponins are hydrolyzed and degraded in the digestive tract and do not cause hemolysis. They must never be administered by injection.
Overdose primarily causes nausea, vomiting, and gastric irritation due to the saponins' local stimulating effect. Administration of platycodin at doses of 5, 10, and 40 mg/kg orally to rats showed that after 7 days, platycodin exerted a stimulatory effect on the gastrointestinal tract and NF-κB expression, with a dose-dependent relationship.
Traditional processing (scraping off the outer bark, soaking in rice water overnight, slicing, and lightly dry-frying) was used to reduce irritation.
Commercially, quality variation is more of a concern than outright adulteration: roots from certain regions may have significantly lower saponin content than traditional producing areas. Sulfur-fumigated material should be avoided, as it degrades active compounds and alters the herb's properties.
The bioavailability of PLD could be improved by being prescribed with Glycyrrhiza uralensis Fisch. (licorice root), which is a pharmacokinetic interaction of note in TCM combination formulas. Major translational liabilities of platycodin D include low oral bioavailability and ADME determinants including limited permeability, efflux, and metabolism. Formal drug–drug interaction studies in humans are not available in the published literature. The anticoagulant activity of PLD noted in preclinical studies warrants caution in patients receiving anticoagulant therapy, though no human data confirming clinically significant interactions exist.
Platycodon grandiflorus root is a plant/plant extract used in some over-the-counter (OTC) products. It is not an approved drug in the United States or European Union for any specific indication. It is recognized as a legal herbal medicine in China, South Korea, and Japan, where it is included in national pharmacopeias.
Health conditions that Platycodon root may help support.
Platycodon root and its principal saponin platycodin D have been shown in preclinical studies to suppress Th2-driven allergic responses, including IgE, IL-4, IL-5, and eosinophil infiltration. Animal models of ovalbumin-induced allergic airway inflammation show reduced airway hyperresponsiveness with platycodon extract treatment. Clinical human data remain limited, but the mechanistic evidence is well-characterized.
Platycodon root ethanol extracts show significant DPPH and ABTS radical-scavenging activity (98.03% and 84.30% respectively at tested concentrations) in validated assays. Phenolic compounds, flavonoids, and saponins are the primary antioxidant constituents. Polysaccharide fractions mitigate H2O2-induced oxidative damage in HepG2 cells.
Platycodon grandiflorum is documented in TCM for asthma and wheezing. Multiple preclinical studies show it reduces eosinophilia, Th2 cytokines (IL-4, IL-5, IL-13), and airway hyperresponsiveness in OVA-induced asthma models via TLR4/NF-κB pathway inhibition. Fermented platycodon extract reduced airway inflammation and cough reflex sensitivity in guinea pig models.
Platycodon root is documented to possess hypotensive activity. A pharmacological review classifies it as 'an inhibitor of the central nervous system, which can reduce blood pressure.' A broader review lists hypotension among its established biological applications. The mechanism appears to involve central nervous system inhibition and vasodilation, though human RCT evidence is absent.
Multiple preclinical studies show platycodon saponins and polysaccharides reduce fasting blood glucose, improve glucose tolerance, and modulate insulin signaling pathways. In one rat study, total saponins (200 mg/kg for 18 weeks) reduced blood sugar and improved liver function in type 2 diabetic animals. In vitro, platycodon extract enhanced insulin-stimulated glucose uptake in muscle cells.
Platycodon root is formally indicated for bronchitis in TCM, Kampo, and Korean traditional medicine, with the Chinese Pharmacopoeia and ethnopharmacological records confirming millennia of use. A 2025 ScienceDirect study found platycodon mitigates cigarette smoke-induced chronic bronchitis inflammation via TLR4/MyD88/NF-κB pathway inhibition. Network pharmacology and phytochemical studies have mapped its multi-target mechanisms.
Multiple animal studies demonstrate platycodon root saponins and dietary powder reduce total cholesterol, LDL-C, and increase HDL-C. A 1996 rat study found 5% dietary platycodon significantly decreased serum and liver cholesterol. Platycodin D enhances LDL receptor (LDLR) expression and LDL uptake in hepatic cells, providing a direct molecular mechanism.
Platycodon root extracts and platycodin D consistently suppress pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), nitric oxide, and iNOS across multiple in vitro and in vivo models. The primary mechanism is inhibition of NF-κB, MAPK, and PI3K/AKT signaling pathways. These effects span respiratory, hepatic, skin, and gut inflammation models.
Platycodon root-derived saponins (Changkil saponins, particularly platycodin D) attenuate atopic dermatitis-like skin lesions in multiple mouse models by restoring Th1/Th2 balance and suppressing NF-κB and STAT1 signaling. Traditional texts record platycodon's use for mastitis and dermatitis from the Ming Dynasty. Evidence is preclinical; no human RCT for dermatitis exists.
A 12-week randomized, double-blind, placebo-controlled trial in 108 overweight Korean adults found that 571 mg/day platycodon root extract significantly reduced body fat mass, body fat percentage, and abdominal/subcutaneous fat areas compared to placebo. Animal studies consistently show anti-adipogenic effects via PPARγ and C/EBPα downregulation.
Platycodon polysaccharides and platycodin D improve insulin sensitivity in animal models by inhibiting α-glucosidase/α-amylase, enhancing AMPK phosphorylation, and increasing glucose uptake in skeletal muscle cells. In vitro, platycodon polysaccharides enhanced glucose uptake and intracellular glycogen in insulin-resistant HepG2 cells.
Platycodon root extracts and platycodin D exhibit hepatoprotective effects in multiple animal models of liver injury, including alcohol-induced, endotoxin-induced, chemotherapy-induced, and diabetic liver damage. Mechanisms include suppression of ALT/AST elevations, reduction of oxidative stress markers, and inhibition of NF-κB-driven hepatic inflammation.
Platycodon root (Platycodon grandiflorus, jie geng) is the pharmaceutical form of balloon flower root used in TCM for respiratory conditions. Its saponins provide expectorant, anti-inflammatory, and bronchodilatory effects supported by preclinical studies. A 2025 PMC study confirmed anti-inflammatory action in asthmatic models via TLR4/NF-κB suppression.
Platycodon root (from Platycodon grandiflorus) is the dried root of balloon flower widely used in TCM for expelling phlegm and treating respiratory catarrh. Modern pharmacological studies confirm significant antitussive, expectorant, and anti-inflammatory effects mediated by its saponins. Jiegeng saponins enhance expectorant effects through gut microbiota metabolism and regulation of arachidonic acid metabolism.
Preclinical studies consistently demonstrate that platycodon root saponins lower serum and liver triglycerides in hyperlipidemic and diabetic animal models. In a 1996 rat study, a 5% platycodon diet significantly decreased serum and liver triglyceride concentrations. Platycodin D reduces serum TG via the AMPK/ACC/CPT-1 fatty acid metabolism pathway.
A 2025 systematic review (PMC/MDPI, Molecules) found platycodon inhibits SARS-CoV and other viruses by blocking viral replication stages and activating T cell and macrophage function. An 8-week randomized controlled trial of red platycodon root extract demonstrated enhancement of human immune function. Platycodin D modulates NF-κB, PI3K/AKT, and MAPK pathways to amplify host antiviral immunity.
Platycodon root has a centuries-long TCM record as a 'pus-draining' herb for lung abscesses and carbuncles. The Chinese Pharmacopoeia explicitly lists abscess among its indications. The classical Jiegeng Decoction was the canonical formula for lung carbuncle (pulmonary abscess). No controlled human trials have isolated platycodon's effect on abscess resolution.
Platycodon root has been used for millennia across Chinese, Japanese, and Korean traditions to treat upper respiratory symptoms associated with colds, including cough, sore throat, and phlegm. The Japanese Kampo formula saikatsugekito, which includes platycodon root, was historically used during influenza pandemics. No placebo-controlled RCTs in cold or influenza patients have been published for platycodon as monotherapy.
In TCM, platycodon root is used for chest pain and lung conditions with purulent or inflammatory pleural involvement. Traditional texts describe its use for 'stabbing pains in the hypochondrium,' and the Chinese Pharmacopoeia lists chest tightness and abscess among its indications. No clinical or preclinical studies specifically testing platycodon for pleurisy have been identified.
Platycodon root has been used in TCM for lung carbuncle and bacterial lung infections historically equivalent to pneumonia. Modern Chinese clinical experience documents its role in treating 'plum pneumonia' (lobar pneumonia). The Chinese Pharmacopoeia's indication for lung abscess with purulent sputum overlaps directly with pneumonia management.
Platycodon root is classified in TCM as a phlegm-transforming and mucus-expelling herb and has been used to address excess upper respiratory mucus production. Platycodin D has been shown in vitro to inhibit IL-13-induced inflammatory cytokine and mucus expression in nasal epithelial cells. No clinical trial specifically targeting post-nasal drip has been conducted.
Across Chinese, Korean, and Japanese traditional medicine systems, platycodon root is a canonical remedy for seasonal respiratory ailments including coughs, congestion, and throat irritation associated with seasonal changes. The Chinese Pharmacopoeia lists these as official indications. Preclinical evidence supports expectorant, anti-inflammatory, and antiviral mechanisms relevant to seasonal respiratory conditions.
TCM texts, including the Ming Dynasty Bencao Mengquan, describe platycodon root as 'clearing the nasal passages.' Its expectorant saponins promote secretion clearance. Platycodin D inhibits mucus production in nasal epithelial cells in vitro. Traditional Pharmacopoeia classification as a phlegm-clearing herb supports this use.
Soothing sore throat is the most historically documented use of platycodon root, listed explicitly in the Chinese Pharmacopoeia and recorded from the Eastern Han Dynasty onward. The herb is classified in TCM as a primary remedy for sore throat with hoarseness. Modern Chinese clinical practice documents its use for chronic pharyngitis and acute/chronic laryngitis.
Platycodon root is the specific preparation of Platycodon grandiflorum root used in TCM for sore throat, pharyngitis, and tonsillitis. It is an active ingredient in Sho-saiko-to-ka-kikyo-sekko, a Japanese Kampo formula clinically studied for chronic tonsillitis management. Platycodin D saponins exert anti-inflammatory and throat-soothing effects.
Platycodon root (Platycodon grandiflorum; Jie Geng) is a primary TCM expectorant herb used for cough, sore throat, and phlegm associated with upper respiratory infections. Its triterpenoid saponins (platycodin D) provide expectorant, anti-inflammatory, and antiviral activity. It is a component of multiple classical URTI formulas including Sang Ju Yin.
Body systems that Platycodon root may help support.
Go back